FDA drug officials pulled few punches at a recent hearing on potential industry user fees for the OTC drug monograph program, recognizing current failings and admitting, frankly, that the agency is struggling to keep up with related science and market developments.
The monograph program was "instituted, really, many, many decades ago. We've been trying to implement it since," said Center for Drug Evaluation and Research Director Janet Woodcock in her opening...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?